Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 405,000 shares of Common Stock and prefunded warrants to purchase 334,000 shares of Common Stock to a single institutional investor.
- Offering Price: $6.25 per share of Common Stock; $6.249 per Prefunded Warrant.
- Net Proceeds: Approximately $4.1 million (after deducting placement agent fees and estimated offering expenses).
- Placement Agent Fee: 6.0% of gross proceeds paid to H.C. Wainwright & Co., LLC.
- Use of Proceeds: Primarily to support a previously announced strategic alternative process and for working capital/general corporate purposes.
Material Changes and Liquidity Outlook
The filing does not provide comparative financial metrics (revenue, profit, or margins) as it reports a specific capital raise event rather than periodic operating results. However, it provides the following liquidity outlook:
- Cash Runway: Management estimates that net proceeds from this offering, combined with current cash and cash equivalents, will be sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2026.
- Ownership Limits: Prefunded Warrants include beneficial ownership limitations, preventing exercise if it causes the holder to exceed 4.99% (or up to 9.99% upon election) of outstanding common stock.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The cash runway estimate is based on assumptions that may prove incorrect; the Company could use available capital resources sooner than expected.
- Strategic Process: Proceeds are explicitly tied to supporting a "strategic alternative process," indicating potential M&A or restructuring activity.
- Risks: Completion of the offering is subject to customary closing conditions. General risks include uncertainties in the research and product development process.
- Legal Opinion: A legal opinion regarding the validity of the securities was filed as Exhibit 5.1.
Key Facts for Investor Verification
- Verify the status and details of the "strategic alternative process" mentioned as a primary use of proceeds.
- Confirm the exact closing date of the offering and the final net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor subsequent filings for updates on the cash runway, particularly if the strategic process extends beyond the projected Q2 2026 timeline.